文献速递基础与转化研究流行病学与生物统计

通过外部研究评估后续伴随诊断设备的药物疗效

Drug Efficacy Estimation for Follow-on Companion Diagnostic Devices Through External Studies.
PubMed 文献 · Stat Med · 2024-11-05

治疗产品通常仅对特定亚组患者安全有效,需伴随诊断设备识别适用人群。后续伴随诊断设备(FCD)开展新随机试验或桥接研究可能不伦理、昂贵或不切实际。本文提出靶向治疗设计的外部研究,结合CCD随机试验数据与FCD外部研究数据,估计FCD+和FCD-亚组中的药物疗效,并通过理论结果、模拟研究及非小细胞肺癌实例验证方法。

要点

  • 提出靶向治疗设计作为现有一致性设计的扩展,用于评估后续伴随诊断设备。
  • 结合CCD随机试验数据与FCD外部研究数据,估计FCD+和FCD-亚组药物疗效。
  • 理论结果和模拟研究验证方法,并在非小细胞肺癌实例中展示应用。

核心结论

  • 提出的靶向治疗设计与统计分析方法可结合CCD随机试验数据和FCD外部研究数据,估计FCD+和FCD-亚组中的药物疗效,从而间接验证FCD。

研究设计与样本

  • 提出一种名为靶向治疗设计的新型外部研究设计,作为现有一致性设计的扩展,并给出相应的统计分析方法。
  • 方法结合FDA批准的对照伴随诊断设备(CCD)的随机试验数据与后续伴随诊断设备(FCD)的外部研究数据。

主要发现

  • 理论结果和模拟研究验证了所提出的方法。
  • 通过非小细胞肺癌的真实实例进一步说明了所提出的方法。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

A therapeutic product is usually not suitable for all patients but for only a subpopulation. The safe and effective use of such a therapeutic product requires the co-approval of a companion diagnostic device which can be used to identify suitable patients. While the first-of-a-kind companion diagnostic device is often developed in conjunction with its intended therapeutic product and simultaneously validated through a randomized clinical trial, there remains room for the innovation of new and improved follow-on companion diagnostic devices designed for the same therapeutic product. However, conducting a new randomized trial or a bridging study for the follow on companion devices may be unethical, expensive or unpractical. Hence, there arises a need for an external study to evaluate the concordance between the FDA-approved comparator companion diagnostic device (CCD) and the subsequent follow-on companion diagnostic devices (FCD), indirectly validating the latter. In this article, we introduce a novel external study design, referred to as the targeted treatment design, as an extension of the existing concordance design. Additionally, we present corresponding statistical analysis methods. Our approach combines the CCD randomized trial data and the FCD external study data, enabling the estimation of drug efficacy within the FCD+ and FCD- subpopulations-the parameters crucial for the validation of the FCD. Theoretical results and simulation studies validate the proposed methods and we further illustrate the proposed methods through an application in a real example of non-small-cell lung cancer.

来源:Stat Med,查看原文。版权归原作者所有。

引用

  1. Sun J, Hu W, Zhou XH, et al. Drug Efficacy Estimation for Follow-on Companion Diagnostic Devices Through External Studies. Stat Med. 2024. PMID: 39501533. doi:10.1002/sim.10231

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。